Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

Healionics wins SBIR grant to conduct STARcuff technology preclinical studies

The National Institutes of Health's (NIH) General Medical Sciences division has awarded $909,165 Phase II small business innovation research (SBIR) grant to Healionics to conduct preclinical studies on its STARcuff anti-infection technology.

The STARcuff, which is made up of STAR Biomaterial, is designed for the treatment of catheter-associated infections caused while performing hemodialysis procedures.

Healionics chief technology officer and research project principal investigator Andrew Marshall said catheters loaded with active antimicrobial agents or antiseptics are a controversial option for chronic dialysis patients due to the serious threat of microbial resistance.

"STARcuff is an attractive approach because it can potentially provide long-term protection against infection without any active agents," Marshall added.